IFNA1 and myeloid sarcoma: Data from a phase III clinical trial involving IFN revealed that serious ADRs were rarely reported and that were mainly represented by cases of depression, suicide attempt, MS aggravation and dystonia, but no one of these cases was classified as definite interferon beta 1a side effect [50].